T. Rowe Price Associates’s Maravai LifeSciences MRVI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $215K | Buy |
88,993
+6,170
| +7% | +$14.9K | ﹤0.01% | 2678 |
|
|
2025
Q1 | $184K | Buy |
82,823
+11,995
| +17% | +$26.6K | ﹤0.01% | 2677 |
|
|
2024
Q4 | $387K | Buy |
70,828
+7,946
| +13% | +$43.4K | ﹤0.01% | 2385 |
|
|
2024
Q3 | $523K | Buy |
62,882
+1,019
| +2% | +$8.48K | ﹤0.01% | 2226 |
|
|
2024
Q2 | $443K | Sell |
61,863
-11,732
| -16% | -$84K | ﹤0.01% | 2236 |
|
|
2024
Q1 | $639K | Buy |
73,595
+3,575
| +5% | +$31K | ﹤0.01% | 2109 |
|
|
2023
Q4 | $459K | Sell |
70,020
-16,087
| -19% | -$105K | ﹤0.01% | 2211 |
|
|
2023
Q3 | $862K | Sell |
86,107
-889,663
| -91% | -$8.91M | ﹤0.01% | 1864 |
|
|
2023
Q2 | $12.1M | Buy |
975,770
+1,030
| +0.1% | +$12.8K | ﹤0.01% | 1041 |
|
|
2023
Q1 | $13.7M | Buy |
974,740
+4,215
| +0.4% | +$59.1K | ﹤0.01% | 1002 |
|
|
2022
Q4 | $13.9M | Sell |
970,525
-328,840
| -25% | -$4.71M | ﹤0.01% | 993 |
|
|
2022
Q3 | $33.2M | Sell |
1,299,365
-348,262
| -21% | -$8.89M | 0.01% | 758 |
|
|
2022
Q2 | $46.8M | Sell |
1,647,627
-401,330
| -20% | -$11.4M | 0.01% | 895 |
|
|
2022
Q1 | $72.3M | Buy |
2,048,957
+102,221
| +5% | +$3.61M | 0.01% | 840 |
|
|
2021
Q4 | $81.6M | Buy |
1,946,736
+418,203
| +27% | +$17.5M | 0.01% | 832 |
|
|
2021
Q3 | $75M | Buy |
1,528,533
+675,951
| +79% | +$33.2M | 0.01% | 872 |
|
|
2021
Q2 | $35.6M | Buy |
852,582
+517,893
| +155% | +$21.6M | ﹤0.01% | 1147 |
|
|
2021
Q1 | $11.9M | Buy |
+334,689
| New | +$11.9M | ﹤0.01% | 1367 |
|